CARDIFF ONCOLOGY INC
NASDAQ: CRDF (Cardiff Oncology, Inc.)
Last update: 22 minutes ago1.91
0.21 (12.35%)
| Previous Close | 1.70 |
| Open | 1.75 |
| Volume | 2,431,136 |
| Avg. Volume (3M) | 1,214,996 |
| Market Cap | 128,658,664 |
| Price / Sales | 225.55 |
| Price / Book | 2.38 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Operating Margin (TTM) | -13,194.49% |
| Diluted EPS (TTM) | -0.930 |
| Quarterly Revenue Growth (YOY) | -46.80% |
| Total Debt/Equity (MRQ) | 1.91% |
| Current Ratio (MRQ) | 6.22 |
| Operating Cash Flow (TTM) | -42.75 M |
| Levered Free Cash Flow (TTM) | -25.76 M |
| Return on Assets (TTM) | -41.00% |
| Return on Equity (TTM) | -74.15% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Cardiff Oncology, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -4.0 |
| Average | -0.50 |
|
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 5.64% |
| % Held by Institutions | 45.29% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Laurion Capital Management Lp | 31 Dec 2025 | 2,646,738 |
| Acorn Capital Advisors, Llc | 31 Dec 2025 | 1,962,084 |
| Blair William & Co/Il | 31 Dec 2025 | 1,948,847 |
| Geode Capital Management, Llc | 31 Dec 2025 | 1,523,015 |
| Franklin Resources Inc | 31 Dec 2025 | 1,205,803 |
| Flputnam Investment Management Co | 31 Dec 2025 | 595,328 |
| Northern Trust Corp | 31 Dec 2025 | 461,753 |
| Goldman Sachs Group Inc | 31 Dec 2025 | 385,086 |
| Candriam S.C.A. | 31 Dec 2025 | 344,437 |
| Bank Of New York Mellon Corp | 31 Dec 2025 | 328,995 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (HC Wainwright & Co., 423.56%) | Buy |
| Median | 8.00 (318.85%) | |
| Low | 6.00 (Piper Sandler, 214.14%) | Buy |
| Average | 8.00 (318.85%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 1.77 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 25 Feb 2026 | 6.00 (214.14%) | Buy | 1.91 |
| HC Wainwright & Co. | 28 Jan 2026 | 10.00 (423.56%) | Buy | 1.62 |
| Date | Type | Details |
|---|---|---|
| 27 Jan 2026 | Announcement | Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC |
| 27 Jan 2026 | Announcement | Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development |
| 09 Dec 2025 | Announcement | Sidoti Events, LLC's Year-End Virtual Investor Conference |
| 08 Dec 2025 | Announcement | Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 |
| 08 Dec 2025 | Announcement | Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |